Trial Profile
A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+ in patients with grass pollen-induced allergic rhinoconjunctivitis during two successive pollen seasons
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Sep 2022
Price :
$35
*
At a glance
- Drugs ABT 011 (Primary)
- Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
- Focus Registrational; Therapeutic Use
- Sponsors DMS Imaging
- 09 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 09 Oct 2020 This trial has been discontinued in Poland, according to European Clinical Trials Database record.
- 22 Jul 2020 This trial has been discontinued in Czech Republic, according to European Clinical Trials Database record.